Research and clinical development of quizartinib (VANFLYTA) as a therapy for the patients with acute myeloid leukemia

Fms-like tyrosine kinase 3 (FLT3) mutations have been found in about 30% of acute myeloid leukemia (AML) cases, and the most common form of FLT3 mutation is internal tandem duplication (ITD) in the juxtamembrane domain, which is associated with poor prognosis.